NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences Inc (NYSE:RCUS) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.02. The firm earned $1.75 million during the quarter, compared to the consensus estimate of $1.34 million. Arcus Biosciences had a negative return on equity of 38.73% and a negative net margin of 1,180.37%. View Arcus Biosciences' Earnings History.

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

5 brokerages have issued 1 year target prices for Arcus Biosciences' stock. Their forecasts range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' stock price to reach $19.25 in the next year. This suggests a possible upside of 88.2% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

Media stories about RCUS stock have been trending very negative this week, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcus Biosciences earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Arcus Biosciences.

Some companies that are related to Arcus Biosciences include Principia Biopharma (PRNB), Pacira Biosciences (PCRX), Forty Seven (FTSV), Arvinas (ARVN), Tricida (TCDA), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), Alder Biopharmaceuticals (ALDR), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), Innoviva (INVA) and Dicerna Pharmaceuticals (DRNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), AcelRx Pharmaceuticals (ACRX), Fate Therapeutics (FATE), Galmed Pharmaceuticals (GLMD), Progenics Pharmaceuticals (PGNX), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $10.23.

Arcus Biosciences has a market capitalization of $469.15 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

The official website for Arcus Biosciences is http://www.arcusbio.com/.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]